Literature DB >> 7495727

CD4-independent in vivo priming of murine CTL by optimal MHC class I-restricted peptides derived from intracellular pathogens.

R Dyall1, L V Vasović, A Molano, J Nikolić-Zugić.   

Abstract

CTL combat intracellular pathogens by killing infected cells. The molecular targets of their attack are foreign peptides bound to self MHC encoded class I molecules. Immunization of mice with peptides containing CTL determinants was shown to elicit CD4-dependent CTL. Here, we have achieved in vivo CTL priming with naturally processed 8-10 amino acid long class I-restricted peptides emulsified in an adjuvant. A potent, reproducible and physiologically relevant response was obtained using peptides from an intracellular bacterium and five viruses (including HIV) in two murine MHC haplotypes. This method is suitable for multiple vaccination, since a 'cocktail' of peptides derived from three pathogens elicited effector CTL against each pathogen. Most importantly, peptide-induced CD8+CD4- CTL were CD4(+)-independent. These results have implications for CTL induction in situations where CD4 T cells are depleted or compromised, as is the case in HIV infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7495727     DOI: 10.1093/intimm/7.8.1205

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  12 in total

1.  In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity.

Authors:  C Sedlik; G Dadaglio; M F Saron; E Deriaud; M Rojas; S I Casal; C Leclerc
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Identification of an immunodominant mouse minor histocompatibility antigen (MiHA). T cell response to a single dominant MiHA causes graft-versus-host disease.

Authors:  C Perreault; J Jutras; D C Roy; J G Filep; S Brochu
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

3.  West Nile virus-specific CD4 T cells exhibit direct antiviral cytokine secretion and cytotoxicity and are sufficient for antiviral protection.

Authors:  James D Brien; Jennifer L Uhrlaub; Janko Nikolich-Zugich
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

4.  Induction of cytotoxic T-cell response by optimal-length peptides does not require CD4+ T-cell help.

Authors:  C Fayolle; U M Abdel-Motal; L Berg; E Deriaud; M Jondal; C Leclerc
Journal:  Immunology       Date:  1996-09       Impact factor: 7.397

5.  Immunization with chaperone-peptide complex induces low-avidity cytotoxic T lymphocytes providing transient protection against herpes simplex virus infection.

Authors:  Udayasankar Kumaraguru; Malgorzata Gierynska; Shanna Norman; Barry D Bruce; Barry T Rouse
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

6.  T cell functions in granulocyte/macrophage colony-stimulating factor deficient mice.

Authors:  H Wada; Y Noguchi; M W Marino; A R Dunn; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

7.  Cutting edge: TLR ligands increase TCR triggering by slowing peptide-MHC class I decay rates.

Authors:  Brian D Rudd; James D Brien; Miles P Davenport; Janko Nikolich-Zugich
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

8.  Age-related CD8 T cell clonal expansions constrict CD8 T cell repertoire and have the potential to impair immune defense.

Authors:  Ilhem Messaoudi; Joël Lemaoult; Jose A Guevara-Patino; Beatrix M Metzner; Janko Nikolich-Zugich
Journal:  J Exp Med       Date:  2004-11-15       Impact factor: 14.307

9.  Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70.

Authors:  Y Moroi; M Mayhew; J Trcka; M H Hoe; Y Takechi; F U Hartl; J E Rothman; A N Houghton
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

10.  T cell receptor (TCR) recognition of MHC class I variants: intermolecular second-site reversion provides evidence for peptide/MHC conformational variation.

Authors:  R Dyall; D H Fremont; S C Jameson; J Nikolić-Zugić
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.